Among patients with FIGO 2014 Stage III-IVA cervical cancer, treatment with pembrolizumab plus CRT significantly reduced the risk of disease progression or death by 41% compared with placebo plus CRT.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti ...

The FDA approved pembrolizumab (Keytruda) with chemoradiotherapy (CRT) for patients with stage III-IVA cervical cancer based on International Federation of Gynecology and Obstetrics (FIGO) 2014 ...

Merck (NYSE:MRK) said the FDA has approved its oncology drug Keytruda in combination with chemoradiotherapy for the treatment of FIGO 2014 Stage III-IVA cervical cancer. The approval is the drug’s ...

The FDA approved pembrolizumab in combination with chemoradiotherapy for the treatment of certain women with stage III to stage IVA cervical cancer. This is the third approved cervical cancer ...

The at-home tests are not yet available, but the U.S. Food and Drug Administration approved two self-swab tests from the ...

A major update to federal women’s health preventive guidance will make it easier for women to get screened for cervical ...

An open surgical approach is preferable to minimally invasive surgery for early-stage cervical cancer and should be considered the standard of care, new data confirm. The current standard surgical ...

Consecutive patients who underwent primary surgery for invasive cervical carcinoma of International Federation of Gynecology and Obstetrics (FIGO) stage I to IIA between 1993 and 2000 were ...

Health Care Utilization and Follow-Up Care in Young Adult Breast Cancer Survivors We performed a nation-wide retrospective matched cohort study of all patients age 18-45 years with Fédération ...